Adaptimmune Therapeutics PLC: Nasdaq/NYSE listing notice — Adaptimmune transfers listing to Nasdaq Capital Market; gets 180-day extension to regain $1.00 bid

Adaptimmune Therapeutics PLC

Approval to transfer ADS listing from Nasdaq Global Select to Nasdaq Capital Market, effective May 2, 2025.
ADSs non-compliant with $1.00 minimum bid price since Nov 1, 2024; 180-day extension now runs to Oct 27, 2025.
To regain compliance, ADS bid price must be at least $1.00 for 10 consecutive business days within extended period.
Failure to comply by Oct 27, 2025 may result in delisting from Nasdaq.
Company monitors bid price and will evaluate actions to satisfy Listing Rule 5450(a)(1).

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Adaptimmune Therapeutics PLC received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

May 1, 2025, Adaptimmune Therapeutics plc (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) approving the transfer of the listing of the Company’s American Depositary Shares (“ADSs”) from the Nasdaq Global Select Market to the Nasdaq Capital Market (the “Approval”). As previously reported on a Current Report on Form 8-K filed with the Securities and Exchange Commission, on November 1, 2024, the Company received a notice from Nasdaq that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), because the minimum bid price of the Company’s ADSs has been be

View on SEC.gov

93 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-25-043522

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.